Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
diabetes mellitus 4 endocrinologydiseases
metformin 2 endocrinologydiseasesdrugs
sitagliptin 48 endocrinologydiseasesdrugs
type 2 diabetes mellitus 3 endocrinologydiseases

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
metformin 6123 is important to remind that these medicines had some alternatives for comparing such as placebo and metformin as shown in Tables 2 and 3. Exclusion criteria were animal studies, non-controlled trial studies, observational
metformin 8438 each of the drugs, but also assessed the efficacy of combination therapy using the drugs together with metformin . However, due to the lack of sufficient studies, we did not assess combination therapy with other drugs,
sitagliptin 65 Title: DARU Journal of Pharmaceutical SciencesLinagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trialsKhosro
sitagliptin 997 country. Hence, this study aimed to compare the clinical efficacy of the two drugs, i.e. linagliptin and sitagliptin , in patients with type 2 diabetes.MethodsA systematic review was conducted to identify all clinical
sitagliptin 1274 with type 2 diabetes. Using keywords such as “linagliptin”, “type 2 diabetes mellitus”, “ sitagliptin ” and related combinations, we searched databases including Scopus, PubMed, and Web of Science. The
sitagliptin 1943 and a total of 13,747 patients. The results showed no significant difference between linagliptin and sitagliptin in terms of key efficacy and safety outcomes such as HbA1c changes from baseline, body weight change
sitagliptin 2376 same.ConclusionsBased on the results, there was no significant difference between the two drugs, i.e. linagliptin and sitagliptin , in terms of efficacy; in other words, the efficacy of the two drugs was the same. Therefore, the use
sitagliptin 4748 DPP-4 decrease the risk of heart diseases in comparison MET. It seems some drugs such as linagliptin, sitagliptin and etc. can be a suitable alternatives for patients who don’t reply to MET [[15]].Also, According
sitagliptin 5227 [[17], [18]]. The aim of this study was also to compare the clinical efficiency of linagliptin and sitagliptin in patients with type 2 diabetes to provide scientific evidences to policy makers for an appropriate
sitagliptin 5465 making.MethodsData resources and search strategyIn order to evaluate the efficacy of the two drugs, linagliptin and sitagliptin , we conducted a systematic review of the studies published by the end of 2015. Using keywords such as
sitagliptin 5633 published by the end of 2015. Using keywords such as “linagliptin”, “type 2 diabetes mellitus”, “ sitagliptin ” and related combinations, we searched databases including Scopus, PubMed, and Web of Science (Additional file 1:
sitagliptin 6007 clinical trial studies published in English that compared the clinical efficacy of linagliptin and sitagliptin . It is important to remind that these medicines had some alternatives for comparing such as placebo
sitagliptin 8103 first we used a systematic review approach to collect studies on the efficiency of the two drugs, i.e. sitagliptin and linagliptin, which are among DPP-4 category. Then, using network meta-analysis, we analyzed the
sitagliptin 8792 criteria:P (Population): Patients with type 2 diabetes.I (Intervention): linagliptin.C (Comparators): sitagliptin .O (Outcomes): The desired outcomes were: “HbA1c change from baseline”, “Percentage of patients
sitagliptin 11188 results of the meta-analysis of the existing combinations and indirectly compared linagliptin 5 mg with sitagliptin 100 mg and also compared LIN 5 mg + MET with SIT 100 mg + MET. In the second table, it was assumed
sitagliptin 11452 with and without MET were the same; thus, we compared linagliptin 5 mg (with and without MET) with sitagliptin 100 mg (with and without MET). For the first two outcomes, we compared the changes from the baseline
sitagliptin 15682 and percentage of patients experiencing hypoglycemic events; these figures compare linagliptin and sitagliptin groups with the placebo group and compare LIN 5 mg + MET and SIT 100 mg + MET groups with PLB + MET
sitagliptin 16204 baselineBased on the results of the meta-analysis presented in Table 2, the two groups of linagliptin and sitagliptin were significantly different from the placebo group in terms of HbA1c changes from baseline, as these
sitagliptin 16979 comparison showed a significant difference in HbA1c from baseline in linagliptin group, as compared with the sitagliptin group; in other words, linagliptin decreased HbA1c by 0.359 units, as compared with sitagliptin (comparison
sitagliptin 17076 the sitagliptin group; in other words, linagliptin decreased HbA1c by 0.359 units, as compared with sitagliptin (comparison 5). However, the changes in LIN 5 mg + MET group, as compared with SIT 100 mg + MET
sitagliptin 18618 shows no significant difference between the linagliptin and placebo groups (comparison 1) and between sitagliptin groups and placebo group (comparison 2) in terms of body weight changes from baseline. However, it had
sitagliptin 19224 meta-analyses were combined and an indirect comparison showed no significant difference between linagliptin and sitagliptin groups in terms of body weight changes from baseline (comparison 5). However, it showed a significant
sitagliptin 19905 that in the placebo group (comparison 1). However, it did not show a significant difference in the sitagliptin group, as compared with the placebo group (comparison 2). In addition, comparing the percentage of HbA1c
sitagliptin 20408 comparison of the percentage of HbA1c <7 showed no significant difference between the linagliptin group and sitagliptin group (comparison 5) and between the LIN 5 mg + MET group and SIT 100 mg + MET group (comparison
sitagliptin 20709 percentage of patients experiencing hypoglycemic events significantly decreased in the linagliptin and sitagliptin groups, as compared with the placebo group; the odds ratio of hypoglycemic events in the two groups
sitagliptin 21518 comparison of hypoglycemic events showed no significant difference between the linagliptin group and sitagliptin group (comparison 5). However, it significantly decreased in the LIN 5 mg + MET group, as compared
sitagliptin 22042 comparisons 2 and 4, there was a significant difference in HbA1c changes from baseline in the linagliptin and sitagliptin groups (with and without MET), as compared with the placebo group; the mentioned drugs, respectively,
sitagliptin 22384 no significant difference between the linagliptin group (with and without MET), as compared with the sitagliptin group (with and without MET) (comparison 9).Table 3Network meta-analysis for comparison HbA1c changes
sitagliptin 23489 weight changes from baseline showed that there was no significant difference between the linagliptin and sitagliptin groups (with and without MET), as compared with the placebo group (with and without MET) (comparisons
sitagliptin 23746 no significant difference between the linagliptin group (with and without MET), as compared with the sitagliptin group (with and without MET) in terms of body weight changes from baseline (comparison 9).Comparing
sitagliptin 23985 percentage of HbA1c <7 revealed that there was a significant difference between the linagliptin and sitagliptin groups (with and without MET), as compared with the placebo group (with and without MET) as the odds
sitagliptin 24136 compared with the placebo group (with and without MET) as the odds ratio of HbA1c in the linagliptin and sitagliptin groups, respectively, was 2.03 and 1.67, as compared with the placebo group (comparisons 7 and 8). However,
sitagliptin 24376 no significant difference between the linagliptin group (with and without MET), as compared with the sitagliptin group (with and without MET) (comparison 9).Comparing the groups in terms of hypoglycemic events showed
sitagliptin 24560 terms of hypoglycemic events showed that there was a significant difference between the linagliptin and sitagliptin groups (with and without MET), as compared with the placebo group (with and without MET) as the odds
sitagliptin 24725 placebo group (with and without MET) as the odds ratio of hypoglycemic events in the linagliptin and sitagliptin groups, respectively, was 0.28 and 0.47, as compared with the placebo group (comparisons 7 and 8). However,
sitagliptin 24956 no significant difference between the linagliptin group (with and without MET), as compared with the sitagliptin group (with and without MET) (comparison 9).DiscussionUsing meta-analyses approach, we performed a direct-comparison
sitagliptin 25273 meta-analysis showed a significant difference in HbA1c changes from baseline in the linagliptin group and sitagliptin group (with and without MET), as compared with the placebo group, because HbA1c was reduced by these
sitagliptin 25773 that there was no significant difference between the linagliptin and placebo groups and between the sitagliptin groups (with and without MET) and placebo group. However, it showed a significant difference in the
sitagliptin 26332 that of the placebo group. However, there was no significant difference in the LIN 5 mg + MET and sitagliptin groups (with and without MET), as compared with the placebo group. Moreover, as to the percentage of
sitagliptin 26547 hypoglycemic events, there was a significant difference in the linagliptin (with and without MET) and sitagliptin groups, as compared with the placebo group. The odds ratio of hypoglycemic events in the two groups
sitagliptin 27088 percentage of hypoglycemic events in the linagliptin group (with and without MET), as compared with the sitagliptin group (with and without MET); thus, the efficiency of the two drugs are identical. Therefore, the results
sitagliptin 27419 results, in certain cases linagliptin has a relative advantage in pharmacokinetic superiority over sitagliptin ; thus, it can be considered as a suitable alternative. Non-renal clearance is one of the pharmacokinetic
sitagliptin 28030 dysfunction is quite common in diabetic patients [[23]–[26]].Although the efficacy of linagliptin and sitagliptin is the same, because the use of linagliptin has no restrictions in patients with renal dysfunction,
sitagliptin 28296 with renal dysfunction, it is necessary to make it accessible in Iran pharmaceutical market along with sitagliptin so that the physicians have an opportunity to prescribe thesedrugs for patients with different background
sitagliptin 29548 expert people and they underwent quality assessment. At the end, this study compared linagliptin and sitagliptin drugs in terms of main efficacy and safety outcomes mentioned above. The results of this study showed
sitagliptin 29712 mentioned above. The results of this study showed no significant difference between linagliptin and sitagliptin in terms of clinical efficiency. Therefore, given their similar level of efficacy, the use of these
sitagliptin 29930 drugs depends on their availability and cost. According to this fact that efficacy of Linagliptin and sitagliptin is not statistically different in terms of main outcomes, any recommendation for use of each of them
sitagliptin 30159 based on cost and renal functionality of patients. For patients with renal impairments who cannot use sitagliptin and are preferred to use DPP4 inhibitors, linagliptin is a good choice. But for other patients, an economic
sitagliptin 30465 perspective in decision making.ConclusionThe results showed no significant difference between linagliptin and sitagliptin in terms of clinical efficacy and they had the same effect. However, as there is no restriction on the
sitagliptin 30742 might be considered as a treatment of choice. Hence, it is recommended to include this drug, along with sitagliptin , in the list of pharmaceuticals in Iran
Select Disease Character Offset Disease Term Instance
diabetes mellitus 101 Title: DARU Journal of Pharmaceutical SciencesLinagliptin versus sitagliptin in patients with type 2 diabetes mellitus : a network meta-analysis of randomized clinical trialsKhosro KeshavarzFarhad LotfiEhsan SanatiMahmood
diabetes mellitus 1249 the two drugs in patients with type 2 diabetes. Using keywords such as “linagliptin”, “type 2 diabetes mellitus ”, “sitagliptin” and related combinations, we searched databases including Scopus, PubMed, and
diabetes mellitus 3571 more than 4.6 million people were affected by the disease in 2015 [[3]]. Recent estimates suggest that diabetes mellitus causes 59,258,034 disability adjusted life years (DALYs) in 2012 with a 89.7% increase in deaths from
diabetes mellitus 5608 review of the studies published by the end of 2015. Using keywords such as “linagliptin”, “type 2 diabetes mellitus ”, “sitagliptin” and related combinations, we searched databases including Scopus, PubMed, and
type 2 diabetes mellitus 94 Title: DARU Journal of Pharmaceutical SciencesLinagliptin versus sitagliptin in patients with type 2 diabetes mellitus : a network meta-analysis of randomized clinical trialsKhosro KeshavarzFarhad LotfiEhsan SanatiMahmood
type 2 diabetes mellitus 1242 compared the two drugs in patients with type 2 diabetes. Using keywords such as “linagliptin”, “ type 2 diabetes mellitus ”, “sitagliptin” and related combinations, we searched databases including Scopus, PubMed, and
type 2 diabetes mellitus 5601 systematic review of the studies published by the end of 2015. Using keywords such as “linagliptin”, “ type 2 diabetes mellitus ”, “sitagliptin” and related combinations, we searched databases including Scopus, PubMed, and

You must be authorized to submit a review.